That's a great question. I think there are two things going

New Post Public Reply Private Reply Replies (0) Message Board
joey68 aheckler1 #618
That's a great question. I think there are two things going on here.

1. Oncoscope's bankruptcy bought by SCIE
2. Duke's creation with Adam Wax and gang on a/LCI technology

Although the two are connected, they are separate as well. Duke isn't just a university. They have licensing departments for students and faculty to use. When Duke members create new technologies the licensing department helps them get the tech to market. Adam Wax and gang (old CEO of Oncoscope) created their tech at Duke. Pretty much the entire gang of Oncoscope worked at Duke.

Adam wax wanted to create a business utilizing this tech. The technology works, but for whatever reason the business failed. This led to bankruptcy.

Even though Duke members created the tech, the separate company 'Oncoscope' had to legally file for bankruptcy. Sure, duke could have bought Oncoscope but I doubt the university is in the business of pulling companies out of bankruptcy.

Instead, Spectrascience, which has known about Oncoscope for years, bought them out. There are old PRs listing Oncoscope as SCIE's competitor.

Buying the bankrupt company doesn't mean that the buyer, SCIE, owns the rights to the technology. Duke apparently has the rights to the tech because Adam Wax and gang created it at Duke. This means (I assume) that although SCIE now owns the tangible assets of Oncoscope, the technology is owned (in some form or another) still by Duke.

Pretty much we're probably going to read a lot of "Specific terms of the agreement were not disclosed" for quite some time.

Quote:
what is stopping duke from licensing it to another company


From a business perspective, I don't see why Duke would license it to another company. Duke must have something SCIE wants and SCIE must have something Duke wants. For right now, that's the only information I can come up with. Someone else may know more.

Having a Licensing Agreement is nothing new or strange. It happens all the time between businesses. In fact, this isn't the first time a Licensing Agreement With Duke University has occurred.

In another post, I wrote about:

Quote:
Vital Images Announces Licensing Agreement With Duke University


Vital Images is a company who, like SCIE, got a Licensing Agreement With Duke. This ultimately led to Vital Images being bought out by Toshiba for $10+ PER share.

http://www.prnewswire.com/news-releases/vital...82542.html

Notice under the terms of agreement for Vital Images:

Quote:
Under the terms of the agreement, the company has the right to Duke's object and source code, to incorporate the software in its current and future medical visualization products, and to make all necessary enhancements and upgrades. Specific terms of the agreement were not disclosed.


I think SCIE's agreement will be similar to this. SCIE probably has the rights to incorporate the software in its current and future medical products, and to make all necessary enhancements and upgrades. At the same time, the ownership of the technology belongs to Duke. Again, in business this happens all the time. Not every company creates their own software; they pay a software company to design it for them.

As a very simple example, anyone using Microsoft Word; I highly doubt any of us created our own version of Microsoft Word. Instead, we buy a license key from Microsoft (when we bought Office) to use the software. Same goes for businesses. Spectrascience doesn't need to spend millions to create a/LCI technology. Instead, SCIE has a licensing agreement with Duke University.

In all, I believe this Duke agreement is going to propel us to the next level. The exposer alone in the past 2 weeks is probably more than we've had in 2 years.

Notice the quote from Duke:

Quote:
Carl Ravin, chairman, Department of Radiology, Duke University Medical
Center, said, "Duke has invested heavily in the development of new radiology
network technologies, including our DICOM software libraries. This
relationship with Vital Images demonstrates that we have developed a high
quality, high performance implementation of DICOM standards. We are pleased
that they selected our software to include in their leading-edge Vitrea
system
."


"they selected our software to include in their leading-edge Vitrea
system" sounds to me like Vital Images chose to use Duke's software; not Duke asked them to use it.

Its also possible part of the agreement with Duke to use their technology was for SCIE to buy the backrupt Oncoscope. Right now, its all guess work, but if Vital Images was bought out for $10+, I'm sticking around to see what happens with SCIE.

SpectraSCIENCE Inc. (SCIE) Stock Research Links

SCIE Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sobi Q3 2026 Report Defies Economic Headwinds

Updated Category News Views 0

Resilience in a Tough Market In a world where every finance report often feels like a gloomy weather forecast, Swedish Orphan Biovitrum AB, or Sobi for short, has come out swinging. They just dropped their Q3 2026 financials, and it's a breath of fresh air in these turbulent economic times. Sobi, primarily dealing in rare diseases, posted an impressive 16% revenue jump....

Continue Reading
Humberto Quintanar Strengthens McKinley Irvin's Seattle Team

Updated Category News Views 141

Humberto Quintanar Makes His Move In a world where legal battles can shake lives to the core, McKinley Irvin is throwing another heavyweight into the ring. They’ve just pulled in Humberto Quintanar, a guy who knows his way around a courtroom like a cabbie knows a city's backstreets. This isn't just another seat-fillin' lawyer; Quintanar packs years of experience as a...

Continue Reading
Globe Life Faces 8% Stock Dip Amidst Legal Scrutiny

Updated Category News Views 120

Trouble Brews for Globe Life Investors Brace yourselves, folks. Globe Life Inc. (NYSE: GL) has found itself slap-bang in the middle of a potentially messy legal quagmire. The $7 million in excess Medicare Supplement claims that popped up due to a snail-like processing delay by the Centers for Medicare & Medicaid Services (CMS) have sent investors scrambling. And oh boy,...

Continue Reading
FOX's Watters Hosts Town Hall with VP Vance

Updated Category News Views 265

What's Brewing Between Jesse Watters and JD Vance? Who would've thought Texas would be the stage for FOX's Jesse Watters and Vice President JD Vance to lock horns over the country's pressing issues? Set your sights on the Lone Star State this October 29th as Watters rolls out the red carpet for Vance during Jesse Watters Primetime. It's a pre-taped town hall meet-up,...

Continue Reading
Centerspace Sale Faces Scrutiny Amid Investor Concerns

Updated Category News Views 40

Potential Undervaluation Looms Large over Centerspace Sale On a crisp October day, the saga of Centerspace's proposed sale to Independence Realty Trust (NYSE: IRT) is stirring the pot. Charles C. Foti, Jr., Esq., and the law firm Kahn Swick & Foti, LLC are throwing a wrench into the works, questioning the soundness of the whole shebang. The deal, valued at 3.800 shares of...

Continue Reading
Turbo VPN Adds 42 Server Locations, Expands Reach

Updated Category News Views 79

Turbo VPN Stretches Its Legs Globally Alright, let's take a dive into what Turbo VPN's up to with their network expansion. They're not just beefing up their presence; they're doubling down with 42 new server locations and heightening their streaming backbone. This isn't just another small tweak; it’s a strategic push that puts them firmly in 105 countries. It’s like...

Continue Reading
2026 World Laureates Forum Drives Science Forward

Updated Category News Views 31

A Meeting of Great Minds in Shanghai Alright, listen up. Shanghai's gearing up to be the nerve center for the 2026 World Laureates Forum (WLF), and it's seething with potential. This ain't your regular science fair; it's a lion's den of brainpower set to crack open the future of science and tech. With the heavy-hitters like Nobel and Turing laureates on the docket, you're...

Continue Reading
GrOwnValve's Personalized Valves Pass Safety Milestone

Updated Category News Views 102

Pioneering Success in Personalized Valve Study GrOwnValve GmbH just hit a big milestone that's caught my attention. Their first-in-human heart valve study wrapped up its six-month run with no prosthesis-related mishaps. Yeah, zero misfires. For five whole patients who've been through the wringer, things held steady. This Berlin startup’s got guts, testing tech that...

Continue Reading
Latham & Watkins Welcomes Privacy Sledgehammer Macko

Updated Category News Views 100

Privacy Enforcer Lands at Latham & Watkins With regulatory pressure turning up the heat, Latham & Watkins has roped in Michael Macko, a seasoned pro when it comes to privacy enforcement. To give you a peek into his credibility, Macko doesn't just have a foot in the door—he built the doorframe himself over at the California Privacy Protection Agency (CalPrivacy)....

Continue Reading
EQS Group's Climate Goals Get SBTi Validation

Updated Category News Views 90

EQS Group's Bold Climate Commitments The news hits like a gust of clean air — EQS Group's climate targets are now stamped with the seal of approval from the Science Based Targets initiative (SBTi). This isn't just your typical corporate green pledge: we're talking serious, validated commitments pushing for net-zero emissions by 2050. Decoding EQS Group's Impactful...

Continue Reading

Top 5 Most Recently Viewed Articles

Sinch Observes Rise in RCS Messaging with iOS 18 Support

Updated Category News Views 99

Growing Interest in RCS Messaging Over 70% of Brands Predict RCS Will Become a Primary Customer Communication Channel Within Five Years. Sinch (Sinch AB (publ)) (XSTO: SINCH), a leader in Customer Communications Cloud solutions, has reported a significant uptick in interest for Rich Communication Services (RCS) and RCS Business Messaging (RBM). Their discussions with a...

Continue Reading
Nutriband Celebrates New Milestone with Patent Approval for Aversa™

Updated Category News Views 140

Nutriband's Patent Notice - A Step Forward for Aversa™ Technology Nutriband Inc. (NASDAQ:NTRB) recently achieved a major milestone in the realm of pharmaceutical innovation by receiving a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its Aversa™ abuse deterrent technology. This exciting development signals the impending issuance of...

Continue Reading
SEGG Media Unveils $300 Million Strategy for Web3 and Digital Assets

Updated Category News Views 152

SEGG Media's Bold Leap into the Future of Digital Assets Today marks a significant turning point for SEGG Media Corporation (NASDAQ: SEGG, LTRYW) as it unveils its ambitious Web3 and Digital Asset Strategy. With a planned investment of $300 million over the next two years, SEGG Media aims to revolutionize the landscape of sports and entertainment by introducing...

Continue Reading
LAVA Therapeutics Reaches Key Milestone in Tender Offer Process

Updated Category News Views 160

LAVA Therapeutics Makes Significant Announcement on Tender Offer Today, LAVA Therapeutics N.V. (Nasdaq: LVTX) revealed a pivotal moment in its tender offer, successfully meeting the minimum share tender condition established for its ongoing acquisition process. In a vibrant report from the Netherlands and Philadelphia, the company announced that an impressive 22,877,463...

Continue Reading
23andMe Strengthens Leadership with Three New Board Directors

Updated Category News Views 289

23andMe Enhances Board Composition with New Directors 23andMe Holding Co. (NASDAQ: ME), a pioneering company in human genetics and preventive health, has recently made significant changes to its Board of Directors. This move is aimed at fostering strategic growth as the company strives to maintain its leadership position in the healthcare market. Introduction of...

Continue Reading